Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CRIS. On March 08, 2018, Curis reported financial results for the fourth quarter and full year ended December 31, 2017. The Company exceeded analysts' estimates for revenue as well as earnings for Q4 FY17. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), which also belongs to the Healthcare sector as the Company Curis. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=ALDX
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Curis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=CRIS
Earnings Highlights and Summary
Curis' total revenues reached $3.26 million for Q4 FY17, reflecting an increase of 38.10% from $2.36 million in Q4 FY16. Curis' revenue for Q4 FY17 mainly included royalty revenues recorded on Genentech and Roche's net sales of Erivedge. Total reported revenue surpassed analysts' consensus estimates by $0.87 million.
Curis' total operating expenses were $10.39 million for Q4 FY17, 20.85% lower than $13.13 million in Q4 FY16. The Company's cost of royalty revenue was $165 million in Q4 FY17, up 36.36% on a y-o-y basis. In the quarter under review, Curis' research and development (R&D) declined 24.46% to $6.92 million on a y-o-y basis and general and administrative (G&A) expenses decreased 14.04% to $3.31 million on a y-o-y basis. The Company reported a loss from operations of $7.13 million in the reported quarter compared to loss from operations of $10.76 million in the previous year's corresponding quarter.
Curis' net loss narrowed to $8.03 million in Q4 FY17 from $11.34 million in Q4 FY16. The Company's net loss per share was $0.05 for the reported quarter versus $0.08 per share in the previous year's comparable quarter. For Q4 FY17, analysts estimated a net loss per share of $0.09 for Curis.
For the year ending December 31, 2017, Curis' total revenues were $9.9 million, which is an increase of 31.50% from $7.53 million in FY16. The Company reported a net loss of $53.32 million in the reported year compared to $60.41 million in the previous year. Curis had a net loss per share of $0.36 in FY17, an increase of 20% from net loss per share of $0.45 in FY16.
Cash Matters
Curis had cash, cash equivalents, and investments of $60.23 million as on December 31, 2017, 35.40% higher than $44.49 million as on December 31, 2016.
The Company's total debt obligations were $41.56 million at the end of FY17 compared to $19.86 million at the end of FY16.
Stock Performance Snapshot
April 18, 2018 - At Wednesday's closing bell, Curis' stock fell 3.57%, ending the trading session at $0.60.
Volume traded for the day: 990.54 thousand shares.
After yesterday's close, Curis' market cap was at $103.08 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
